Patents Represented by Attorney Joseph J. Borovian
  • Patent number: 5543426
    Abstract: 3,7-disubstituted indole derivatives of formula I ##STR1## wherein R.sub.1, R.sub.2, n, X, Y and Z are as defined in the description, are useful for the treatment of psychiatric disorders.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: August 6, 1996
    Assignee: Sandoz Ltd.
    Inventors: Arnold K. Dixon, Rudolf K. A. Giger
  • Patent number: 5538971
    Abstract: 6-hydroxy or 6-alkoxy-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoxalines bearing in position 4 an optionally substituted phenyl group may be used in the treatment of schizophrenia, drug abuse or self-injurious behavior.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: July 23, 1996
    Assignee: Sandoz Ltd.
    Inventors: Peter Gull, Rudolf Markstein, Robert Swoboda
  • Patent number: 5538739
    Abstract: The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.
    Type: Grant
    Filed: January 18, 1991
    Date of Patent: July 23, 1996
    Assignee: Sandoz Ltd.
    Inventors: David Bodmer, Jones W. Fong, Thomas Kissel, Hawkins V. Maulding, Jr., Oskar Nagele, Jane E. Pearson
  • Patent number: 5530008
    Abstract: 5-HT.sub.3 Receptor antagonists are useful in treating panic disorders or obsessive compulsive disorders.
    Type: Grant
    Filed: January 24, 1994
    Date of Patent: June 25, 1996
    Assignee: Sandoz Ltd.
    Inventors: Alberto E. Azcona, Pamela Taylor
  • Patent number: 5519044
    Abstract: The invention provides use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent.
    Type: Grant
    Filed: December 7, 1993
    Date of Patent: May 21, 1996
    Assignee: Sandoz Ltd.
    Inventors: Assunta Imperato, Dietmar Romer
  • Patent number: 5510353
    Abstract: Compounds of formulaA--X--Y--NH--Bwherein A is derived from optionally substituted benzothiophene, indole, 4-aza-and 7-aza-benzothiophene or-indole, A bearing in position 5 hydrogen, halogen, optionally substituted alkyl, hydroxy, nitro, amino, alkylamino, acylamino, alkoxycarbonyl, sulfamoyl, cyano, trimethylsilyl, carboxy, carbamoyl, phosphate, oxycarbamoyl, heterocyclic radical or ether or ester group, X-Y is --CR.sub.8 .dbd.N-- or CH(R.sub.8)--NH-- wherein R.sub.8 is -H or alkyl and attached at position 3 of A, and B is a heterocyclic radical or a residue ##STR1## wherein R.sub.10 is H, optionally substituted alkyl, cycloalkyl, aryl, adamantyl, acyl or carbamoyl and X.sub.2 is alkylthio or NR.sub.3 R.sub.10 wherein R.sub.3 is H or alkyl or R.sub.3 and R.sub.10 together with the nitrogen atom to which they are attached form a heterocyclic radical, in free form or in salt form, have pharmacological activity, e.g. for treating gastrointestinal disorders.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: April 23, 1996
    Assignee: Sandoz Ltd.
    Inventors: Rudolf K. A. Giger, Henri Mattes
  • Patent number: 5504246
    Abstract: A process for preparing carboxylates of polyoxyalkylene siloxanes and -amines, alkylpolyoxyalkylenes, polyoxyalkylene block polymers, alkylamidepolyoxyalkylenes and alkylpolyglucosides comprising subjecting a primary hydroxyl group-containing polyoxyalkylene compound or alkylpolyglucoside to mild oxidiation. The invention also relates to the novel polyoxyalkylene amine and alkylamidepolyoxyalkylene carboxylates prepared by the process.
    Type: Grant
    Filed: June 30, 1994
    Date of Patent: April 2, 1996
    Assignee: Sandoz Ltd.
    Inventors: Parfait J. Likibi, Robert V. Casciani, Gregory L. McCraw
  • Patent number: 5488135
    Abstract: The invention concerns the compounds of formula I ##STR1## wherein the substituents have various significances, in free form and, where such forms exist, in salt form. The compounds have potent antihyperproliferative/antiinflammatory and anticancer activity.
    Type: Grant
    Filed: October 16, 1992
    Date of Patent: January 30, 1996
    Assignee: Sandoz Ltd.
    Inventors: Peter Nussbaumer, Anton Stutz
  • Patent number: 5403868
    Abstract: Novel capsaicin derivatives of general formula I ##STR1## wherein R, R.sub.1 to R.sub.7 and X may be a variety of substituents, processes for the production thereof, pharmaceutical compositions containing them and use thereof as pharmaceuticals.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: April 4, 1995
    Assignee: Sandoz Ltd.
    Inventors: Derek J. Reid, Christopher S. J. Walpole, Roger Wrigglesworth
  • Patent number: 5338730
    Abstract: A process for preparing the (R) stereoisomer of 2,2-bis(hydroxmethyl)-tetrahydrofuran monobutyrate comprising subjecting the dibutyric ester of the 2,2-bis(hydroxymethyl)-tetrahydrofuran to enzymatic hydrolysis. The invention also relates to the novel (R) stereoisomer prepared by the instant process and to its more stable forms. In addition, the invention relates to the use of the (R) stereoisomer in preparing stereoisomers of pharmacologically active compounds and to certain specific stereoisomers produced thereby.
    Type: Grant
    Filed: June 4, 1993
    Date of Patent: August 16, 1994
    Assignee: Sandoz Ltd.
    Inventors: Heinrich Estermann, Prasad K. Kapa, Russell L. Underwood, William J. Houlihan
  • Patent number: 5334756
    Abstract: A process for preparing carboxylates of polyoxyalkylene siloxanes and -amines, alkylpolyoxyalkylenes, polyoxyalkylene block polymers, alkylamidepolyoxyalkylenes and alkylpolyglucosides comprising subjecting a primary hydroxyl group-containing polyoxyalkylene compound or alkylpolyglucoside to mild oxidiation. The invention also relates to the novel polyoxyalkylene amine and alkylamidepolyoxyalkylene carboxylates prepared by the process.
    Type: Grant
    Filed: March 26, 1991
    Date of Patent: August 2, 1994
    Assignee: Sandoz Ltd.
    Inventors: Parfait J. M. Likibi, Robert V. Casciani, Gregory L. McCraw
  • Patent number: 5321016
    Abstract: The invention discloses certain substituted .alpha.-aminoacids having the formula ##STR1## where m and n are 1 or 2, and R, R.sub.1, R.sub.2, R.sub.3 and Y have various significances, which compounds are useful in treating epilepsy, disorders associated with excess GH or LH secretion, anxiety, schizophrenia, depression, CNS degenerative disorders, cerebral hypoxic conditions and stress-related psychiatric disorders.
    Type: Grant
    Filed: September 18, 1992
    Date of Patent: June 14, 1994
    Assignee: Sandoz Pharmaceuticals Corp.
    Inventors: Paul L. Herrling, Werner Muller
  • Patent number: 5312819
    Abstract: The invention concerns pharmaceutical compositions comprising clozapine and a radical scavenger.
    Type: Grant
    Filed: August 2, 1991
    Date of Patent: May 17, 1994
    Assignee: Sandoz Ltd.
    Inventors: Volker Fischer, Ronald P. Mason
  • Patent number: 5300422
    Abstract: A screening method for detecting the vulnerability of patients on clozapine therapy to developing agranulocytosis which comprises establishing the concentration of N-desmethylclozapine in the blood or bone marrow of said patient. In addition, a method of determining patient sensitivity to N-desmethylclozapine is provided which comprises collecting heparinized blood and assaying it for stem cell sensitivity to N-desmethylclozapine.
    Type: Grant
    Filed: December 4, 1991
    Date of Patent: April 5, 1994
    Assignee: Case Western Reserve University
    Inventors: Stanton L. Gerson, Herbert Meltzer
  • Patent number: 5284836
    Abstract: The invention discloses certain heterocyclic, thioether, keto-ester and alkyl phospholipids, e.g., heterocyclic phospholipids having the formula ##STR1## where R is n-C.sub.14 -C.sub.20 alkyl or O-n-C.sub.14 -C.sub.20 alkyl; each R.sub.1 is methyl or ethyl; n is 2-6; and X is --CH.sub.2 --m, where m is 2-4, CH.sub.2 CH.sub.2 O or CH.sub.2 CH.sub.2 S, or a corresponding hydrate thereof, which compounds are useful in treating multiple sclerosis.
    Type: Grant
    Filed: December 4, 1992
    Date of Patent: February 8, 1994
    Assignee: Sandoz Ltd.
    Inventor: William J. Houlihan
  • Patent number: 5272168
    Abstract: The invention provides use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent.
    Type: Grant
    Filed: January 15, 1993
    Date of Patent: December 21, 1993
    Assignee: Sandoz Ltd.
    Inventors: Assunta Imperato, Dietmar Romer
  • Patent number: 5272154
    Abstract: 3,7-disubstituted indole derivatives of formula I ##STR1## wherein R.sub.1, R.sub.2, n, X, Y and Z are as defined in the description are useful for the treatment of psychiatric disorders.
    Type: Grant
    Filed: December 18, 1991
    Date of Patent: December 21, 1993
    Assignee: Sandoz Ltd.
    Inventors: Arnold K. Dixon, Rudolf K. A. Giger
  • Patent number: 5260321
    Abstract: Use of calcium antagonists of formula I ##STR1## wherein the substituents have various significances in the treatment of conditions related directly or indirectly to ionized calcium levels in the blood and combinations of calcium antagonists, e.g. of formula I, with calcitonins.
    Type: Grant
    Filed: July 12, 1991
    Date of Patent: November 9, 1993
    Assignee: Sandoz Ltd.
    Inventors: Robert P. Hof, Moise Azria
  • Patent number: 5229377
    Abstract: A process for preparing the (R) stereoisomer of 2,2-bis(hydroxmethyl)-tetrahydrofuran monobutyrate comprising subjecting the dibutyric ester of the 2,2-bis(hydroxymethyl)-tetrahydrofuran to enzymatic hydrolysis. The invention also relates to the novel (R) stereoisomer prepared by the instant process and to its more stable forms. In addition, the invention relates to the use of the (R) stereoisomer in preparing stereoisomers of pharmacologically active compounds and to certain specific stereoisomers produced thereby.
    Type: Grant
    Filed: April 26, 1991
    Date of Patent: July 20, 1993
    Assignee: Sandoz Ltd.
    Inventors: Heinrich Estermann, Prasad K. Kapa, Russell L. Underwood, William J. Houlihan
  • Patent number: 5223399
    Abstract: Certain patients undergoing clozapine drug therapy may be vulnerable to agranulocytosis. It has been found that agranulocytosis vulnerability is correlated with the presence of HLA antigens B38, DR4 and DQw3. Accordingly, a method is provided for detecting such patients, and an HLA kit is provided.
    Type: Grant
    Filed: March 19, 1991
    Date of Patent: June 29, 1993
    Assignees: Long Island Jewish Medical Center, Dana-Farber Cancer Institute
    Inventors: Jeffrey A. Lieberman, Edmond J. Yunis